AstraZeneca Pharma India and Sun Pharmaceutical Industries will promote Sodium Zirconium Cyclosilicate in India. Each company will market the therapy under a separate brand. The treatment is used for hyperkalaemia in adults.
Source: AstraZeneca Pharma India Limited Press Release (NSE Exchange Filings) | Published on Nov 17, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from AstraZeneca Pharma India and its news (NSE Exchange Filings), the company has formed a second brand partnership with Sun Pharmaceutical Industries. The partnership covers the promotion and distribution of Sodium Zirconium Cyclosilicate in India. AstraZeneca will sell the therapy as Lokelma. Sun Pharma will sell it as Gimliand. The therapy is used for treating hyperkalaemia in adults. The update highlights the agreed-upon brand names and the scope of the partnership.
Also read: JSW Infrastructure Eyes 51% Stake In Oman Port SPV With US$419 Mn Investment
AstraZeneca Pharma India and Sun Pharma will market SZC in India.
AstraZeneca will sell the therapy as Lokelma.
Sun Pharma will market the therapy as Gimliand.
SZC is used for hyperkalaemia treatment in adults.
The arrangement covers promotion and distribution.
AstraZeneca Pharma India has shared the structure of the partnership. Both companies will promote and distribute the therapy. They will operate under their own brand names. AstraZeneca will use the name Lokelma. Sun Pharma will use the name Gimliand.
The partnership covers the Indian market. The therapy supports adults with high potassium levels. The companies have stated only the promotion and distribution details.
Sodium Zirconium Cyclosilicate is used to treat hyperkalaemia. Hyperkalaemia occurs when potassium builds up in the blood. The therapy is meant for adults. The release states this clearly.
Both companies will promote the therapy under separate brand names. Each firm will manage its own marketing plan. The agreement highlights the shared therapy but separate branding. This update adds to the list of therapy announcements made in the Indian market.
Description | Details |
Therapy Name | Sodium Zirconium Cyclosilicate |
Use | Hyperkalaemia in adults |
AstraZeneca Brand | Lokelma |
Sun Pharma Brand | Gimliand |
Arrangement Type | Promotion and distribution |
Coverage | India |
On 17 November 2025 at 15:30 PM IST, the AstraZeneca Pharma India share price stood at ₹9,135.00. The previous close was ₹9,153.00. The stock opened at ₹9,235.00. The day’s high was ₹9,235.00, and the low was ₹9,115.50. The VWAP recorded was ₹9,157.34.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading